These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33383911)

  • 21. Surgical Treatment of Medullary Thyroid Cancer.
    Machens A; Dralle H
    Recent Results Cancer Res; 2015; 204():187-205. PubMed ID: 26494390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
    Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma.
    Ruiz-Garcia E; Vidal-Millan S; Lopez-Yañez A; Torres JAP; Guadarrama-Orozco JA; Lino-Silva LS; Meneses-Garcia A; Astudillo-de la Vega H; Garcia MG
    Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):218-222. PubMed ID: 28166591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence.
    Abou Azar S; Tobias J; Applewhite M; Angelos P; Keutgen XM
    J Clin Endocrinol Metab; 2024 Oct; 109(11):2729-2734. PubMed ID: 38651609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [
    Wang Y; Du LL; Hou SH; Han CZ; Zhao XW; Wang WG; Xu XQ; Jing JX
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Nov; 51(11):873-876. PubMed ID: 27938622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
    Toledo RA; Hatakana R; Lourenço DM; Lindsey SC; Camacho CP; Almeida M; Lima JV; Sekiya T; Garralda E; Naslavsky MS; Yamamoto GL; Lazar M; Meirelles O; Sobreira TJ; Lebrao ML; Duarte YA; Blangero J; Zatz M; Cerutti JM; Maciel RM; Toledo SP
    Endocr Relat Cancer; 2015 Feb; 22(1):65-76. PubMed ID: 25425582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p.Ser891Ala RET gene mutations in medullary thyroid cancer: Phenotypical and genealogical characterization of 28 apparently unrelated kindreds and founder effect uncovering in Northern Italy.
    Giacché M; Panarotto A; Tacchetti MC; Tosini R; Campana F; Mori L; Cappelli C; Pirola I; Lombardi D; Pezzola DC; Casella C; Castellano M
    Hum Mutat; 2019 Jul; 40(7):926-937. PubMed ID: 30927507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma.
    Censi S; Galuppini F; Clausi C; Battheu F; Manso J; Piva I; Corvaglia S; Pedron MC; Mondin A; Iacobone M; Torresan F; Merante Boschin I; Bertazza L; Barollo S; Pennelli G; Mian C
    Thyroid; 2024 Feb; 34(2):177-185. PubMed ID: 38047536
    [No Abstract]   [Full Text] [Related]  

  • 30. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
    Moura MM; Cavaco BM; Pinto AE; Leite V
    J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sporadic minute medullary thyroid carcinoma with a double RET mutation: A case report.
    Yamamoto H; Ishii J; Chiba T; Nakazato Y; Hirano K; Kamma H
    Pathol Int; 2017 Nov; 67(11):580-584. PubMed ID: 28952196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness.
    Ceolin L; Siqueira DR; Ferreira CV; Romitti M; Maia SC; Leiria L; Crispim D; Ashton-Prolla P; Maia AL
    Eur J Endocrinol; 2012 May; 166(5):847-54. PubMed ID: 22345297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: Results from the largest MTC cohort and meta-analysis.
    Mishra V; Kowtal P; Rane P; Sarin R
    Cancer Med; 2019 Oct; 8(13):6151-6161. PubMed ID: 31408923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Child with RET proto-oncogene codon 634 mutation.
    İnce D; Demirağ B; Ataseven E; Oymak Y; Tuhan H; Karakuş OZ; Hazan F; Abacı A; Özer E; Mutafoglu K; Olgun N
    Turk J Pediatr; 2017; 59(5):590-593. PubMed ID: 29745123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
    Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B
    Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymorphisms Within the
    Gemignani F; Romei C; Ciampi R; Corrado A; Melaiu O; Figlioli G; Bonotti A; Foddis R; Cristaudo A; Pellegrini G; Vivaldi A; Cipollini M; Landi S; Elisei R
    Thyroid; 2020 Nov; 30(11):1579-1588. PubMed ID: 32228166
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of 3'UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma.
    Ceolin L; Romitti M; Siqueira DR; Vaz Ferreira C; Oliboni Scapineli J; Assis-Brazil B; Vieira Maximiano R; Dias Amarante T; de Souza Nunes MC; Weber G; Maia AL
    PLoS One; 2016; 11(2):e0147840. PubMed ID: 26829565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
    Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
    Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The correlation between the expression of ATF4 and procalcitonin combined with the detection of
    Ma S; Wang H; Li W; Yan Z; Luo X; Lu P
    Can J Physiol Pharmacol; 2022 Jan; 100(1):19-25. PubMed ID: 34822305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer.
    Loveday C; Josephs K; Chubb D; Gunning A; Izatt L; Tischkowitz M; Ellard S; Turnbull C
    J Clin Endocrinol Metab; 2018 Nov; 103(11):4275-4282. PubMed ID: 29590403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.